| lifestyle modification + metformin vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.71 [0.35 1.45] | p=1.00 | 0 | 109 | 2 | IDDP (Ramachandran),Jarret, | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| metformin vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | no data | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| metformin vs placebo | No demonstrated result suggested Diabetes by 31% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.69 [0.58 0.84] | p=0.04 | 0 | 2506 | 6 | US-DPP (metformin) (Knowler),Li,Charles,Lehtovirta,Orchard,Rodriguez-Moctezuma, | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rosiglitazone and metformin vs placebo | No demonstrated result suggested Diabetes by 75% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | NaN [NaN NaN] | p=1.00 | 0 | 122 | 1 | CANOE, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.25 [0.10 0.62] | p=0.04 | 0 | 122 | 1 | CANOE, | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| lifestyle modification + metformin vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.71 [0.35 1.45] | p=1.00 | 0 | 109 | 2 | IDDP (Ramachandran),Jarret, | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| metformin vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.66 [0.37 1.18] | p=1.00 | 0 | -36 | 2 | US-DPP (metformin) (Knowler),Li, | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| rosiglitazone and metformin vs placebo | No demonstrated result suggested Diabetes by 75% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| normoglycemia | NaN [NaN NaN] | p=1.00 | 0 | 122 | 1 | CANOE, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | cardiovascular death, MI, stroke | no data | | Diabetes | 0.25 [0.10 0.62] | p=0.04 | 0 | 122 | 1 | CANOE, | | hospitalisation for heart failure | no data | | All cause death | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
